A clinical trial of a new stem cell-derived pancreatic islet cell treatment for type 1 diabetes, by Vertex Pharmaceuticals, is moving forward. According to Vertex, the therapy, called VX-880, has the potential to restore the body’s ability to normalize blood glucose levels through restoration of pancreatic islet cell function. Read more